2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-177621A
    Cevolisiran sodium
    		Inhibitor
    Cevolisiran sodium, a siRNA, is a complement component 3 (C3) synthesis reducer.
    Cevolisiran sodium
  • HY-163379
    C5aR1 antagonist 2
    		Antagonist
    C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC50 values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 2
  • HY-147080B
    Avacincaptad pegol sodium scrambled negative control
    		Inhibitor
    Avacincaptad pegol sodium scrambled negative control is the sequence scrambled negative control of Avacincaptad pegol sodium.
    Avacincaptad pegol sodium scrambled negative control
  • HY-177611A
    Agazisiran sodium
    		Inhibitor
    Agazisiran sodium, a siRNA,is a complement factor B synthesis reducer.
    Agazisiran sodium
  • HY-N7166
    3-O-(2'E,4'Z-Decadienoyl)ingenol
    		Inhibitor
    3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that exhibits significant anticomplement activity with an IC50 of 89.5 μM.
    3-O-(2'E,4'Z-Decadienoyl)ingenol
  • HY-172239
    Tarvicopan
    		Inhibitor
    Tarvicopan is an inhibitor for complement factor D.
    Tarvicopan
  • HY-P991485
    Anti-CD88/C5AR1 Antibody (G2_anti-C5aR)
    		Inhibitor
    Anti-CD88/C5AR1 Antibody (G2_anti-C5aR) is a human monoclonal antibody (mAb) targeting C5AR1.
    Anti-CD88/C5AR1 Antibody (G2_anti-C5aR)
  • HY-177621B
    Cevolisiran sodium scrambled negative control
    		Inhibitor
    Cevolisiran sodium scrambled negative control is the sequence scrambled negative control of Cevolisiran sodium.
    Cevolisiran sodium scrambled negative control
  • HY-14648S1
    Dexamethasone-d5-1
    		Inhibitor
    Dexamethasone-d5-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>5</sub>-1
  • HY-177621
    Cevolisiran
    		Inhibitor
    Cevolisiran, a siRNA, is a complement component 3 (C3) synthesis reducer.
    Cevolisiran
  • HY-P991657
    MEDI7814
    		Inhibitor
    MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury.
    MEDI7814
  • HY-17627R
    Avacopan (Standard)
    		Inhibitor
    Avacopan (Standard) is the analytical standard of Avacopan. This product is intended for research and analytical applications. Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
    Avacopan (Standard)
  • HY-W587516
    Bisphenol A bissulfate disodium
    		Inhibitor
    Bisphenol A bissulfate disodium is a metabolite of Bisphenol A (HY-18260). Bisphenol A bissulfate disodium (compound 7) show complement-inhibiting activity with an IC50 of 247 μM.
    Bisphenol A bissulfate disodium
  • HY-W727837
    Bisphenol S disulfate disodium
    Bisphenol S disulfate disodium has an inhibitory effect on complement (IC50 = 660 μM) .
    Bisphenol S disulfate disodium
  • HY-102034R
    Complement factor D-IN-1 (Standard)
    Complement factor D-IN-1 (Standard) is the analytical standard of Complement factor D-IN-1 (HY-102034). This product is intended for research and analytical applications. Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.
    Complement factor D-IN-1 (Standard)
  • HY-157472
    ACT-1014-6470
    		Antagonist
    ACT-1014-6470 is an orally active, potent, reversible, and selective C5aR1 antagonist. ACT-1014-6470 demonstrates potent inhibition of C5aR1 activation. ACT-1014-6470 can be used in the research of inflammatory diseases.
    ACT-1014-6470
  • HY-P10639A
    C5aR2 agonist P32 acetate
    		Agonist
    C5aR2 agonist P32 (Ac-RHYPYWR-OH) acetate is a C5aR2-selective agonist. C5aR2 agonist P32 acetate has been shown to elicit multiple immunomodulatory activities, both by down-regulating the C5aR1-mediated cell signalling, and acting in a C5aR1-independent fashion, in vitro and in vivo.
    C5aR2 agonist P32 acetate
  • HY-P3502B
    Zilucoplan (PEG2)
    		Inhibitor
    Zilucoplan (PEG2) is a Zilucoplan (HY-P3502) derivative, where the linker section replaces PEG24 by PEG2. Zilucoplan is a potent complement component 5 (C5) inhibitor.
    Zilucoplan (PEG2)
  • HY-W130878
    4-Octylphenol
    		Activator
    4-Octylphenol is a hormone disruptor that has gender-specific effects on male reproductive cells, significantly reducing the mitotic index and the number of spermatogonia. 4-Octylphenol can cause inflammatory damage to fish gills by activating the complement system through the C3a/C3aR axis and the C5a/C5aR1 axis, this leads to complement activation and causes immune suppression due to the imbalance between Th1/Th2 cells and regulatory T cells (Treg)/Th17 cells, as well as inflammatory damage via the Toll-like receptor 7 (Toll-like Receptor (TLR))/IκBα/NF-κB pathway.
    4-Octylphenol
  • HY-147607
    Lanoracopan
    		Inhibitor
    Factor B-IN-5 (Example 5 target compound) is a potent complement factor B inhibitor, with an IC50 of 1.2 μM. Factor B-IN-5 can be used for the research of diseases related to inflammation and immunity.
    Lanoracopan
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity